StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.1
  1. Startseite
  2. /Verbindung

3-Benzoyl-alpha-methylbenzolessig-säure

Ketoprofen

HCID 3825
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
22071-15-4
Standard-SMILES
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
InChIKey
DKYWVDODHFEZIM-UHFFFAOYSA-N
Summenformel
C16H14O3
Durchschnittliche Molmasse
254,28 g/mol
Monoisotopische Masse
254,09429431

Überblick

Ketoprofen is an oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2. It has a role as a non-steroidal anti-inflammatory drug, an antipyretic, an EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor, a xenobiotic, an environmental contaminant and a drug allergen. It is a member of benzophenones and an oxo monocarboxylic acid. It is functionally related to a propionic acid.

Namen und Bezeichner

Bevorzugter Name
Ketoprofen
IUPAC
2-(3-benzoylphenyl)propanoic acid
Lokaler Name
3-Benzoyl-alpha-methylbenzolessig-säure
Englischer Name
Ketoprofen
Summenformel
C16H14O3
Molmasse
254.28

Namen und Synonyme

ketoprofen22071-15-42-(3-Benzoylphenyl)propanoic acid2-(3-Benzoylphenyl)propionic acidOrudisCapistenActronOruvailAlrheumatKetoprofeneAneolm-Benzoylhydratropic acid
Weitere Namen anzeigen
ProfenidKETOPROFEN USP2-(3-benzoylphenyl)-propionicaci(2RS)-2-(3-Benzoylphenyl)propanoic acid
3-Benzoylhydratropic acidIso-KKetoprofenoOrudis KTRP-19583SectorKetoprofenumKetorin

Datenbank-Bezeichner

CAS
22071-15-4
PubChem CID
3825
DTXSID
DTXSID6020771
ChEMBL
CHEMBL571
ChEBI
CHEBI:6128
UNII
90Y4QC304K
EC Number
244-759-8
Nikkaji
J3.468A

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
3,1
Polarare Oberfläche (TPSA)
54,4 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
3
Frei drehbare Bindungen
4
Schwere Atome
19
Formalladung
0
Komplexität
331

Experimentelle und physikochemische Eigenschaften

Drugs · 4 Einträge

DEA NFLIS-Drug Category -> Analgesics

Pharmaceuticals -> NSAIDs

Pharmaceutical

Pharmaceuticals

LogP · 2 Einträge

3.2

3.12

Solubility2.13e-02 g/L
Human Drugs · 3 Einträge

Breast Feeding; Lactation; Milk, Human; Analgesic Agents; Anti-inflammatory Agents, Nonsteroidal

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Animal Drugs · 3 Einträge

Active Ingredients (Ketoprofen) -> FDA Greenbook

Pharmaceuticals -> Animal Drugs -> Approved in Taiwan

Pharmaceuticals -> UK Veterinary Medicines Directorate List

Melting Point94 °C
Physical DescriptionSolid
Dissociation Constants · 4 Einträge

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 5 Einträge

This chemical does not meet GHS hazard criteria for 0.1% (1 of 672) of reports.

Danger

H301 (99.7%): Toxic if swallowed [Danger Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P280, P301+P316, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 672 reports by companies from 29 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory Information · 2 Einträge

Status: Active Update: 30-06-2020 https://echa.europa.eu/registration-dossier/-/registered-dossier/24605

Ketoprofen: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - Benzeneacetic acid, 3-benzoyl-.alpha.-methyl-: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 3 (99.7%)

Toxikologische Informationen

Hepatotoxicity · 1 Eintrag

Prospective studies show that 1% to 2% of patients taking ketoprofen experience at least transient serum aminotransferase elevations. These may resolve even with drug continuation. Marked aminotransferase elevations (>3 fold elevated) occur in

Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 5 Einträge

M02AA10

M - Musculo-skeletal system

M - Musculo-skeletal system

QM - Musculo-skeletal system

QM - Musculo-skeletal system

Protein Binding99% bound, primarily to albumin
Pharmacodynamics · 1 Eintrag

Ketoprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. Ketoprofen has pharmacologic actions similar to those of other prototypical NSAIDs, which inhibit prostaglandin synthesis. Ketoprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and alleviate moderate pain.

Mechanism of Action · 1 Eintrag

The anti-inflammatory effects of ketoprofen are believed to be due to inhibition cylooxygenase-2 (COX-2), an enzyme involved in prostaglandin synthesis via the arachidonic acid pathway. This results in decreased levels of prostaglandins that mediate pain, fever and inflammation. Ketoprofen is a non-specific cyclooxygenase inhibitor and inhibition of COX-1 is thought to confer some of its side effects, such as GI upset and ulceration. Ketoprofen is thought to have anti-bradykinin activity, as well as lysosomal membrane-stabilizing action. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.

Biological Half-LifeConventional capsules: 1.1-4 hours <p>Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)</p>
Metabolism/Metabolites · 2 Einträge

Rapidly and extensively metabolized in the liver, primarily via conjugation to glucuronic acid. No active metabolites have been identified.

Ketoprofen has known human metabolites that include Ketoprofen glucuronide.

FDA Pharmacological Classification · 6 Einträge

90Y4QC304K

Zugehörige Reaktionen

54
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 163579
HRID 163579als ProduktTraining data from https://doi.org/10.1039/C8SC04228D (9/10)
Reaktionsgleichung von HRID 179402
HRID 179402als EduktTraining data from https://doi.org/10.1039/C8SC04228D (6/10)
Reaktionsgleichung von HRID 371111
HRID 371111als Eduktuspto-grants-1985_07
Reaktionsgleichung von HRID 373356
HRID 373356als Eduktuspto-grants-1992_11
Reaktionsgleichung von HRID 478092
HRID 478092als Produktuspto-grants-1989_12
Reaktionsgleichung von HRID 597796
HRID 597796als Eduktuspto-grants-2011_03
Reaktionsgleichung von HRID 620971
HRID 620971als Produktuspto-grants-1989_04
Reaktionsgleichung von HRID 620972
HRID 620972als Produktuspto-grants-1989_04
ZurückSeite 1 von 7

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

3.98

4

3.8

4.45

Collision Cross Section · 4 Einträge

155.4 Ų [M+H]+ [CCS Type: TW]

157.5 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

148.63 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

165.87 Ų [M+Na]+

Physikochemische Eigenschaften

Schmelzpunkt
93 · 93-96°C
Siedepunkt
357.5 °C · 357.5°C (rough estimate)
Dichte
1.1565 · 1.1565 (rough estimate)
Brechungsindex
1.56 · 1.5600 (estimate)
storage temp.
2 · 2-8°C
Löslichkeit
Slightly soluble in chloroform and methanol.
pka
5.94 · pKa 5.94(MeOH/H2O) (Uncertain)
Aggregatzustand
solid
Farbe
White to Off-White
Biologische Quelle
synthetic
Wasserlöslichkeit
209 mg/L · 209mg/L(room temperature)
Merck
14 · 14,5305
Major Application
forensics and toxicologypharmaceutical (small molecule)
InChI
1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)
InChIKey
DKYWVDODHFEZIM-UHFFFAOYSA-N
SMILES
CC(C(O)=O)c1cccc(c1)C(=O)c2ccccc2
CAS Datenbank
22071 · 22071-15-4(CAS DataBase Reference)
NIST chemische Informationen
Ketoprofen(22071-15-4)
EPA chemische Informationen
3 · Benzeneacetic acid, 3-benzoyl-.alpha.-methyl- (22071-15-4)

Ketoprofen

vLess-DILI-concern

3

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

wgk
3
tsca
TSCA listed
ridadr
2811
hs_code
29183000
RTECS-Nr.
UE7570000
risk_code
25-36/37/38-23/24/25
Toxizität
LD50 orally in rats: 101 mg/kg (Ueno)
hazard_code
T
safety_code
26-45-36/37/39
hazard_class
6.1(b)
packing_group
III
Speicherklasse
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Hazard Classifications
Acute Tox. 3 OralAquatic Acute 1Eye Irrit. 2Skin Irrit. 2

KETOPROFEN

Mechanisms of Action [MoA] - Cyclooxygenase Inhibitors

Chemical Structure [CS] - Anti-Inflammatory Agents, Non-Steroidal

Established Pharmacologic Class [EPC] - Nonsteroidal Anti-inflammatory Drug

Ketoprofen is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of ketoprofen is as a Cyclooxygenase Inhibitor.

MeSH Pharmacological Classification · 2 Einträge

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.

Absorption, Distribution and Excretion · 3 Einträge

Ketoprofen is rapidly and well-absorbed orally, with peak plasma levels occurring within 0.5 to 2 hours.

In a 24 hour period, approximately 80% of an administered dose of ketoprofen is excreted in the urine, primarily as the glucuronide metabolite.

Oral-dose cl=6.9 +/- 0.8 L/h [Ketoprofen Immediate-release capsules (4 × 50 mg)]

Cellular LocationsCytoplasm
Metabolite PathwaysKetoprofen Action Pathway

Verwendung und Herstellung

UsesUse (kg) in Switzerland (2009): >250
Use Classification · 2 Einträge

Animal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients

Pharmaceuticals -> Animal Drugs -> Approved in Taiwan

General Manufacturing InformationBenzeneacetic acid, 3-benzoyl-.alpha.-methyl-: INACTIVE

Anwendungen

VerwendenKetoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

SchwefelsureMethyljodid3-BenzoylphenylacetonitrilNatriumEthanol3-Benzoylphenylessigsure

Nachgelagerte Produkte

Phthalid3-Acetylbenzoic acid

Ergänzende Hinweise

DefinitionChEBI: An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.